Is Aprea Therapeutics, Inc. overvalued or undervalued?

As of 12 August 2025, the valuation grade for Aprea Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.57 and an EV to EBITDA ratio of 0.63, which suggest that the market is not valuing the company favorably compared to its peers. Additionally, the Return on Capital Employed (ROCE) is exceptionally high at 631.77%, but this is misleading due to the negative Return on Equity (ROE) of -83.51%.
In comparison to its peers, Aprea Therapeutics has a lower EV to EBITDA ratio than Cosmos Health, Inc. at -2.6396 and Lisata Therapeutics, Inc. at 0.1349, both of which are also classified as risky. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -54.41% compared to the index's 12.22%, reinforcing the notion that Aprea Therapeutics is currently overvalued in the market.